Cencora, Inc. $COR Stake Boosted by Vise Technologies Inc.

Vise Technologies Inc. grew its stake in shares of Cencora, Inc. (NYSE:COR) by 94.4% during the 4th quarter, HoldingsChannel reports. The fund owned 8,288 shares of the company’s stock after acquiring an additional 4,024 shares during the period. Vise Technologies Inc.’s holdings in Cencora were worth $2,799,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of COR. Oakworth Capital Inc. purchased a new position in shares of Cencora during the 4th quarter valued at $26,000. Elyxium Wealth LLC bought a new stake in Cencora in the fourth quarter worth $27,000. Archer Investment Corp boosted its holdings in Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares in the last quarter. IAG Wealth Partners LLC bought a new stake in Cencora in the third quarter worth $30,000. Finally, Caitlin John LLC bought a new stake in Cencora in the third quarter worth $31,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Stock Up 1.7%

COR stock opened at $274.94 on Friday. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54. The company has a 50-day moving average of $292.70 and a two-hundred day moving average of $330.55. The stock has a market capitalization of $53.49 billion, a price-to-earnings ratio of 21.08, a price-to-earnings-growth ratio of 1.48 and a beta of 0.59.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. During the same quarter last year, the company earned $4.42 earnings per share. The firm’s revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities research analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora announced that its board has initiated a share buyback plan on Thursday, May 21st that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to purchase up to 3.9% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Friday, May 15th. Cencora’s dividend payout ratio is 18.40%.

Analyst Upgrades and Downgrades

COR has been the subject of a number of recent research reports. Wells Fargo & Company decreased their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a report on Monday, May 11th. Weiss Ratings cut shares of Cencora from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 22nd. UBS Group upped their price objective on shares of Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. JPMorgan Chase & Co. upped their price objective on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Finally, Robert W. Baird decreased their price objective on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Twelve analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $380.25.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.